CD19 and mantle cell lymphoma: Brexucabtagene autoleucel (brexu-cel) is another CD19-targeting CAR T-cell approved for the management of R/R B-cell acute lymphoblastic leukemia and R/R mantle cell lymphoma (MCL) [99,100].